Inotersen targets the TTR mRNA to inhibit the production of misfolded hepatic TTR protein and was found in a phase 3 trial to improve the course of neurologic disease and quality of life in people with hTTR [35]. The gene discussed is TTR; the disease is nervous system disorder.